ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

PeopleandPicks.com is Zacks' Community Website
Find great stocks and great stock pickers in our online community. It's social, it's profitable and it's Free! Join the fun at PeopleandPicks.com

Quote:

Search for Ticker

Free Membership

Search:

OGXI: Oncogenex Pharmaceuticals Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

ONCOGENEX PHARMACEUTICALS INC (NASD)
OGXI	32.06	0.05	(0.16%)	Vol. 162,457	16:00 ET

ONCOGENEX PHARMACEUTICALS is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 and SN2310 are in Phase 1 clinical development; and CSP-9222 and OGX-225 are currently in pre-clinical development.

General Information

ONCOGENEX PHARM

1522 217th Place SE Suite 100 Bothell, WA 98021 Phone: 425-487-9500 Fax: 425-489-0626 Web: www.sonuspharma.com Email: info@sonuspharma.com.

Industry	MED-DRUGS
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	03/10/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	32.01
52 Week High	42.99
52 Week Low	2.23
Beta	2.16
20 Day Moving Average	79,700.80
Target Price Consensus	53.5

% Price Change
4 Week	2.60
12 Week	-12.66
YTD	967.00

% Price Change Relative to S&P 500
4 Week	-1.32
12 Week	-21.16
YTD	791.63

Share Information
Shares Outstanding (millions)	6.03
Market Capitalization (millions)	192.96
Short Ratio	5.51
Last Split Date	08/21/2008

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	-0.34
Current Year EPS Consensus Estimate	-1.98
Estimated Long-Term EPS Growth Rate	-
Next EPS Report Date	03/10/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	1.00
30 Days Ago	1.00
60 Days Ago	1.00
90 Days Ago	1.00

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	-671.43%
vs. Previous Quarter	51.22%

Sales Growth
vs. Previous Year	-%
vs. Previous Quarter:	-%

Price Ratios
Price/Book	17.54
Price/Cash Flow	-
Price / Sales	-

ROE
09/30/09	-127.18
06/30/09	-71.72
03/31/09	-30.99

ROA
09/30/09	-86.47
06/30/09	-50.40
03/31/09	-23.09

Current Ratio
09/30/09	6.08
06/30/09	3.05
03/31/09	-

Quick Ratio
09/30/09	6.08
06/30/09	3.05
03/31/09	-

Operating Margin
09/30/09	-
06/30/09	-
03/31/09	-

Net Margin
09/30/09	-
06/30/09	-
03/31/09	-

Pre-Tax Margin
09/30/09	-
06/30/09	-
03/31/09	-

Book Value
09/30/09	1.82
06/30/09	0.71
03/31/09	-

Inventory Turnover
09/30/09	-
06/30/09	-
03/31/09	-

Debt-to-Equity
09/30/09	0.11
06/30/09	0.32
03/31/09	-

Debt to Capital
09/30/09	10.28
06/30/09	24.13
03/31/09	-


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research